Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Accenture (ACN) call put ratio 1 call to 1.2 puts into quarter results
- Arm Holdings falls as CFO stock sale weighs on sentiment
Fulcrum Therapeutics Inc. (FULC) Prices 6.6M Share Offering at $19/sh
August 12, 2021 5:46 AM EDTFulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering are being sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to 990,000 additional shares... More
Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst
August 10, 2021 1:34 PM EDTEarlier today, Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced positive interim results from its ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.
Results from the MAD portion of the trial demonstrated proof of biology as evidenced by a dose proportional induction in HBG mRNA and accompanying increases in HbF-containing reticulocytes... More
Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%
August 10, 2021 11:27 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) Halted on LUDP, Up 114%
Fulcrum Therapeutics Inc. (FULC) Climbs 48%
August 10, 2021 8:29 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) Climbs 48%
Earlier Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease... More